|
 |
About SAH
In subarachnoid hemorrhage (SAH), rupture of an intracranial aneurysm is the initial insult that causes bleeding, most frequently into the subarachnoid space and less commonly into the intravascular and intracerebral spaces.1 Bleeding may result in brain damage, decreased cerebral perfusion, brain shift and herniation, and hydrocephalus. Patients who survive the initial insult are at risk of secondary complications for the next three weeks, notably aneurysmal rebleeding and cerebral vasospasm.2
Approximately 25% of patients die from the immediate hemorrhage or as a consequence of secondary complications, and 50% of those patients who survive become seriously disabled.3
SAH is a medical emergency requiring the immediate application of appropriate diagnosis and therapeutic measures.4 If you are an Emergency Care Expert, click here for more information.
Sources:
- Macdonald RL. Drug treatment of aneurysmal subarachnoid haemorrhage. CNS Drugs 1996;5:264-277
- Weir B. Protection of the brain after aneurysmal rupture. Can J Neurol Sci 1995;22:177-186.
- Mayberg MR, Batjer HH, Dacey R et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Hearth Association. Stroke 1994;25:2315-2328.
- Weibers WO, Torner JC, Meissner MD. Impact of unruptured intracranial aneurysm on public health in the United States. Stroke 1992;23:1416-1419.
|
|
|
|
Epidemiology:
How widespread is SAH? When does it occur? Who does it affect? Find out here.
Risk Factors:
Discover which patients are more likely to be at risk for SAH, and what factors may help reduce that risk. Click here.
Clinical Manfestations:
Learn to recognize the symptoms of SAH. Find out more.
Diagnosis:
How are patients with SAH diagnosed? Click here to find out.
Classification of SAH:
Find out how the neurological status of SAH is classified by the Hunt and Hess Scale. Click here.
Therapeutic Measures:
Learn how patients with SAH are treated and how further damage is prevented. Learn here.
|
|
|
DO NOT ADMINISTER NIMOTOP INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE-THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMOTOP CAPSULES HAVE BEEN INJECTED PARENTERALLY
(See
WARNINGS and DOSAGE AND ADMINISTRATION.) |
| |
- In patients with SAH, Nimotop® controls damage with a low side effect profile.
- Decreased blood pressure is the most common side effect, occurring in 4.4% of patients. Blood pressure should be monitored during therapy.1
- Other side effects occurring at a low frequency of ≥1.0% include headache, nausea, and bradycardia.1
- No clinically significant effects on hematologic factors, renal or hepatic function, or carbohydrate metabolism have been causally associated with oral nimodipine.1
- Nimotop® does not appear to affect anesthetic management.2
|
| |
Sources:
- Nimotop® (nimodipine) Capsules Prescribing
Information December 2005
- Stullken EH, Johnston WE, Prough DS. Implications of nimodipine prophylaxis of cerebral vasospasm on anesthetic management during intracranial aneurysm clipping. J. Neurosurg. 1985; 62:200-205.
|
|
© Bayer HealthCare Pharmaceuticals.
Bayer HealthCare Pharmaceuticals
6 West Belt
Wayne, NJ 07470
The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the US.
|
|
|
